GPR35

Capital will Support Continued Development of First-in-Class GPR35 Inhibitor Program for the Treatment of Ulcerative Colitis Utilizing Biomarker-Driven, Precision Medicine Strategy OXFORD, United Kingdom, April 15, 2025 /PRNewswire/ -- ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced the closing of a bridge round of financing, which included a strategic investment from AbbVie Ventures, along with support from an existing investor Canaan and new investor Mayewell Capital. The funds will support the continued development of the company's first-in-class GPR35 inhibitor program, which is currently advancing through preclinical development, including investigational new drug (IND)-enabling studies designed to pave the way for initiation of first-in-human clinical trials. "Despite recent advances, patients with Inflammatory Bowel Disease (IBD) are still suffering," said Timothy Radstake, M.D., Ph.D., vice president and global head of immunology discovery research, AbbVie. "Abbvie Ventures invests in opportunities to deliver future pipeline substrates with the potential to break through the therapeutic ceiling in diseases like IBD. We are excited to partner with ThirtyFiveBio to explore the potential therapeutic benefit of targeting GPR35 for the treatment of IBD." GPR35 is a genetically validated target in inflammatory bowel disease, including ulcerative colitis. ThirtyFiveBio and its collaborators have shown that gain-of-function variants of GPR35 are associated with disease. Using human biology, patient data, and patient-derived assays, the company is also demonstrating that GPR35 inhibition is a modality with the potential to resolve underlying disease by preventing epithelial cell damage and dysfunction in the gut wall rather than symptomatic inflammation. In this way, GPR35 inhibition can be considered an "epithelial shield." As such, GPR35 is a differentiated and orthogonal approach to direct anti-inflammatory modalities with the potential to deliver a novel mechanism of treatment that will improve disease resolution and remission rates. Supported by the company's work with several world-leading academic GPR35 and clinical colitis specialists, ThirtyFiveBio is uniquely pursuing antagonism of GPR35 in patients with ulcerative colitis with first-in-class small molecule inhibitors. The company is leveraging informatic analysis of patient tissue to identify subsets of patients who are enriched for GPR35 inhibitor responsiveness based on their unique genetic signatures and biology. The resulting biomarkers for GPR35 inhibitor responsiveness, once validated, will provide the means for precision patient selection in planned clinical trials. "We believe that we occupy a unique and advantageous position within the GPR35-targeted therapeutic space based on our deep understanding of GPR35 biology and how it contributes to GI-related diseases, including colitis and gut cancers. Our discussions with the teams at AbbVie Ventures, as well as Canaan and Mayewell Capital, generated an appreciation for both our competitive differentiation and scientific thought leadership," said James Westcott, Ph.D., chief executive officer of ThirtyFiveBio. "The support from these premier investors offers great validation for the work that our team has already undertaken in this area, as well as the broad therapeutic potential of the platform moving forward. We are eager to continue to advance the program toward the clinic with the goal of establishing proof-of-concept in patients and will be looking for further partners to come on board to support these aims through a syndicated Series A later this year." About ThirtyFiveBio ThirtyFiveBio Limited is a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease. The company has built scientific thought leadership in the biology of GPR35 and the role that it plays in GI disease, including digestive tract colitis and cancers. ThirtyFiveBio has leveraged its fully enabled drug discovery platform to identify multiple unique families of first-in-class small-molecule GPR35 inhibitors with priority molecules in development candidate nomination studies. Created by Molecule to Medicine (MTM), a unique drug discovery and development ecosystem, and Canaan Partners, the company has raised nearly $25 million in financing to date. ThirtyFiveBio is headquartered on Milton Park, a key science precinct south of Oxford, UK. For more information, please visit: . To learn more about MTM please visit: . Contacts: ThirtyFiveBio James Westcott Chief Executive Officer P: +44 (0)1235 644980 [email protected] Vida Strategic Partners (on behalf of ThirtyFiveBio) Tim Brons (Media) 415-675-7402 [email protected] SOURCE ThirtyFiveBio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and 12 months ended 31 December 2024. The full report can be viewed here. Chris Cargill, President & CEO of Nxera, commented: “2024 was a transformational year for Nxera during which we made excellent progress under our new company name and brand towards becoming a leading technology driven biopharmaceutical company bringing new medicines to patients in Japan and globally. “We made fantastic commercial progress, with two products – PIVLAZ™ and QUVIVIQ™ (partnered with Shionogi) – recently launched in Japan driving top line revenue growth. We plan to make these products available to patients in South Korea shortly, in addition to other key APAC markets (ex-China). “Furthermore, and importantly, we saw significant advances across our partnered pipeline in 2024, with multiple programs moving towards late-stage clinical development and generating approximately US$90 million in upfront and milestone payments. These programs address some of the fastest growing therapeutic areas of unmet need, including neurology/neuropsychiatry, metabolic diseases and immunology and inflammation. The progress made by partner Neurocrine to advance its muscarinic agonist portfolio during the year has been particularly exciting and will lead to the first Nxera-designed molecule entering Phase 3 trials in 2025. “Our three wholly owned programs are also advancing as planned in early clinical development, with several important milestones expected over the next 12-18 months. Further, the continued investment in our NxWave™ platform, alongside our collaborations with cutting-edge technology companies, is generating exciting new discovery opportunities within the GPCR target universe, and potentially beyond to other important transmembrane target classes, such as ion channels or transporters. In addition, it allows us to explore new modalities against GPCR targets of interest, such as peptides and antibodies, broadening our capabilities and opportunities even more. “Going into 2025, Nxera is well capitalized and very well positioned – with multiple clinical data readouts and other potential catalysts expected during the year – to build on the tremendous work done by our exceptional and dedicated team, as we continue our mission to bring innovative therapies to patients in Japan and around the world.” Operational Highlights for Q4 2024 Significant growth in PIVLAZ® (clazosentan sodium) 150mg sales in Japan during first full year of Nxera ownership Rapidly becoming standard of care in Japan with neurosurgeons for prevention of cerebral vasospasm in patients with aneurysmal subarachnoid haemorrhage (aSAH)Market share increased from 57% in 2023 to 69% in 2024Q4 2024 net sales of JPY 4,282 million, FY 2024 net sales of JPY 12,651 million (US$83.5 million, representing 14% growth vs FY 2023) QUVIVIQ™ (daridorexant) 25 and 50 mg launched in Japan for the treatment of adult patients with insomnia Insomnia affects about 20% of Japanese adults and is recognized as an important national issue impacting both physical and mental health.QUVIVIQ™ is a novel dual orexin receptor agonist that was successfully developed through a Phase 3 trial by Nxera Pharma Japan (“NPJ,” a wholly owned subsidiary of Nxera Pharma).QUVIVIQ™ was launched in December 2024 under a commercial partnership agreement signed in October 2024 with Shionogi, which is solely responsible for distribution and sales of QUVIVIQ™ in Japan. NPJ is responsible in part for provision of drug product. Strategy to expand market for daridorexant underway with start of Phase 3 trial in South Korea Insomnia affects an estimated 15-25% of the adult population in South Korea, or 6.5-11 million people. The randomized, double-blind, placebo-controlled Phase 3 study in adult and elderly subjects with insomnia is expected to run for 12 months with results expected during 1H 2026. Further progress in sleep/wake disorders made by partner Centessa, which initiated a Phase 2 trial of ORX750 ORX750 is an investigational, orally administered, highly potent and selective orexin receptor 2 agonist, designed using Nxera technology to target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and other sleep-wake disorders. New multi-target partnership and licensing agreement with UK techbio company Antiverse to design antibodies for validated but challenging GPCR targets The collaboration combines Antiverse’s generative AI antibody design expertise with Nxera’s NxWave™ platform, with Nxera retaining exclusive rights to develop and commercialize any resulting candidates. Experienced Pharma Executive Makoto Sugita, M.D., Ph.D., MBA, Appointed as Chief Medical Officer and President of NPJ Dr. Sugita was formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – he brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of global pharmaceutical companies. Nxera Pharma won Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024 Awards recognize outstanding advancements and innovations in the Japanese pharma and biotech sector. Post-period Events Clinical development progress with partnered muscarinic agonist portfolio noted by Neurocrine at 43rd Annual J.P. Morgan Healthcare Conference NBI-1117568 (an oral, muscarinic M4-selective agonist) End of Phase 2 meeting with the US Food & Drug Administration completed and reiteration of plans to begin Phase 3 studies in schizophrenia in 1H 2025.Initiate Phase 2 study in bipolar mania in 2H 2025. NBI-1117570 (a dual M1 / M4 agonist) Initiate Phase 2 study in schizophrenia in 2H 2025. NBI-1117567 (an M1-preferring agonist) and NBI-1117569 (an M4-preferring agonist) Phase 1 trials underway targeting neurological and neuropsychiatric conditions with data readouts anticipated during 2025. Operational Highlights for Full Year 2024 Corporate highlights Nxera Pharma, the new name for Sosei Heptares, came into effect on 1 April 2024 along with the launch of a new corporate brand and identity designed to capture the Group’s ambition to be at the forefront of the next era of biopharmaceuticals and medicineSenior team strengthened with appointments of experienced biopharma executives Toshihiro Maeda as Chief Operating Officer and senior strategy consultant Patrick Branch as Head of Business Development for Japan and APAC Progress with in-house programs Approval of QUVIVIQ™ (daridorexant) 25 and 50 mg by the Ministry of Health, Labour and Welfare of Japan for the treatment of adult patients with insomnia received in September 2024First subject dosed in a Phase 1 trial with NXE0033744, a novel, potent, selective and gut-restricted EP4 receptor agonist in development for the treatment of Inflammatory Bowel Disease (IBD) Full ownership of NXE0027477 regained from GSK – NXE-477 is a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in development as a potential new treatment for IBD. Nxera and PrecisionLife expanded their 2022 strategic R&D partnership into autoimmune disorders with the aim of identifying new drug targets and subsequently potential precision targeted therapies for complex, chronic conditions. Progress with partnered programs Approximately US$70 million in milestone payments received by Nxera based on progress made across multiple partnered programs Neurocrine presented positive Phase 2 data for schizophrenia candidate NBI-‘568 and announced its intention to advance it into Phase 3 trials in 2025, triggering a US$35 million payment to Nxera.Successful completion of long-term preclinical toxicity program with NBI-‘568, supporting its chronic dosing in future clinical trials, triggered a US$15 million payment from Neurocrine First R&D milestone reached under a multi-target discovery collaboration with AbbVie in neurological diseases resulted in a payment of US$10 million to NxeraProgress made by Centessa advancing ORX750 into and through Phase 1 development resulted in a milestone payment to Nxera of US$4.6 million US$2.5 million milestone payment received from Formosa Pharmaceuticals for US approval of APP13007 for the treatment of post-operative inflammation and pain following ocular surgery New global collaboration and exclusive option-to-license agreement signed with Boehringer Ingelheim to develop first-in-class treatments targeting all symptoms of schizophrenia Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Nxera with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaNxera received EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totalling up to EUR 670 million plus tiered royalties Financial Highlights for the 12-month Period ended 31 December 2024 Revenue totalled JPY 28,835 million (US$190.4 million*), an increase of JPY 16,069 million (US$99.6 million) vs. the prior year. This increase was primarily due to the inclusion of NPJ in the scope of consolidation from July 2023 resulting in twelve months of PIVLAZ® sales being included in 2024 compared to circa five months in 2023, as well as signing one new R&D partnership agreement and the occurrence of five R&D milestone events in the current year vs. no upfront fees and the occurrence of three R&D milestone events in the prior year. R&D expenses totalled JPY 11,816 million (US$78.0 million), an increase of JPY 1,741 million (US$6.3 million) vs. the prior year. This increase primarily reflects an increased investment in R&D plus the impact of the weaker Yen. JPY 1,483 million (US$9.8 million) has been included for R&D expenses relating to NPJ/NPK.SG&A expenses totalled JPY 16,015 million (US$105.8 million), an increase of JPY 6,050 million (US$34.8 million) vs. the prior corresponding period. This increase was primarily due to an increase in SG&A expenses relating to the NPJ/NPK businesses, including an amortization charge on Idorsia related intangible assets. JPY 8,972 million (US$59.3 million) has been included for SG&A expenses relating to NPJ/NPK.Operating loss totalled JPY 5,423 million (US$35.8 million) vs. an operating loss of JPY 9,526 million (US$67.8 million) in the prior year. This improvement in profitability reflects the combined effect of all movements explained above.Loss before income tax totalled JPY 4,662 million (US$30.8 million) vs. a loss before income tax of JPY 10,680 million (US$76.0 million) in the prior year. This improvement in profitability reflects the combined effect of all movements explained above.Net loss for the year ended 31 December 2024 totalled JPY 4,838 million (US$31.9 million) vs. a net loss of JPY 7,193 million (US$51.2 million) in the prior year. This improvement in profitability reflects the combined effect of all movements explained above.Core operating profit** totalled JPY 3,606 million (US$23.8 million) vs. a core operating loss of JPY 3,076 million (US$21.9 million) in the prior corresponding period. Cash and cash equivalents as at 31 December 2024 amounted to JPY 32,268 million (US$205.8 million) having decreased by JPY 16,797 million (decreased by US$142.1 million) from the beginning of the year. *Convenience conversion to US$ at the following rates: FY 2024: 1US$ =151.43 JPY; FY 2023: 1US$ =140.53 JPY; 31 Dec 2024: 1US$ = 156.83 JPY; 31 Dec 2023: 1US$ = 141.03 JPY ** Core operating profit / loss is an alternative performance measure which adjusts for material non-cash costs and one-off costs in order to provide insights into the recurring cash generation capability of the core business. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery NxWaveTM platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit www.nxera.life LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsKentaro Tahara, VP Investor Relations and Corporate StrategyShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5210 3399 | +44 (0)1223 949390 | IR@Nxera.life MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@medistrava.com Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Attachment FY24YE Tanshin_NxeraPharma

Second Prestigious BMC Grant in Under a Year will Enable Creation and Validation of Biomarker-Driven Process for Precisely Selecting Patients Most Likely to Respond to GPR35 Inhibition Company Narrows Initial Therapeutic Focus to Ulcerative Colitis with Precision Medicine Strategy for Clinical Development Validating Non-Dilutive Grant Funding Supports Ongoing Fundraising Efforts as Company Continues on Path Toward Clinic OXFORD, United Kingdom, July 2, 2024 /PRNewswire/ -- ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced that the company, along with its long-standing academic collaborator, Nicole Kaneider, Ph.D., of the University of Cambridge, have been awarded a highly competitive Biomedical Catalyst (BMC) grant from Innovate UK, the UK's innovation agency. The grant, for a total of £643,371 (~$817,000), will fund preclinical research designed to enable the company to pursue a precision medicine approach to patient selection for the clinical development of its first-in-class GPR35 inhibitors. While the company's unique approach to GPR35 inhibition has potential application broadly across GI disease and cancers, ThirtyFiveBio is focusing its initial development activities on inflammatory GI conditions driven by epithelial dysfunction such as ulcerative colitis. For this research project, ThirtyFiveBio and Dr. Kaneider will work collaboratively to identify subsets of patients who are enriched for GPR35 inhibitor responsiveness based on their unique genetic signatures. This will involve the deployment of bioinformatics and multi-omics to analyze clinical datasets and cross-reference those with preclinical data generated with relevant cell line and unique disease model platforms. Once this blueprint for GPR35 inhibitor responsiveness is created, the researchers will work to validate the genetic signature in additional preclinical studies, thus providing the company with biomarkers that can be used for precision patient selection in planned clinical trials. "Receiving a second BMC grant from Innovate UK in less than a year is incredibly validating for the ThirtyFiveBio team and the pioneering work we are undertaking on GPR35 inhibition. As we continue to advance our preclinical program in this area, we learn more about the key role that GPR35 plays within the upstream causal biology of inflammatory GI diseases. It is this opportunity to engage at the source of disease activity that has driven our decision to elevate conditions such as ulcerative colitis to the top of our target indication list," said James Westcott, Ph.D., chief executive officer of ThirtyFiveBio. "We look forward to continuing to collaborate with Dr. Kaneider on this latest project and benefiting from her significant expertise on the biological function of GPR35 in GI disease. This work will be instrumental in supporting both the advancement of our GPR35 inhibitor program toward the clinic, as well as our ongoing fundraising efforts." The role of GPR35 in GI diseases is genetically validated and provides a differentiated approach to disease treatment by focusing on underlying and unresolved epithelial and myeloid cell dysfunction, rather than directly addressing inflammation. Several drug developers are advancing programs designed to address the target, though to date, virtually all these efforts have been focused on increasing the activity of GPR35 with targeted agonists. However, important recent scientific findings, including key insights from the ThirtyFiveBio team, support the hypothesis that GPR35 antagonism may represent a more appropriate therapeutic approach by blocking unwanted GPR35 signaling. Based on this evolved scientific perspective, supported by the company's work with several world-leading, academic GPR35 specialists, ThirtyFiveBio is uniquely pursuing antagonism of the target with first-in-class small molecule GPR35 inhibitors. Supporting the company's focus on GPR35 inhibition is a collection of pre-clinical data generated by its scientists that highlights the association between GPR35 mutations and GI diseases. This includes research showing that GPR35 variants are linked to inflammatory bowel disease, and that GPR35 expression is upregulated in GI cancers. The company and Dr. Kaneider have also shown that pathogenic mutations of GPR35 drive its increased expression and function. Furthermore, study results have demonstrated that commonly dysregulated GI-cancer genes can be reversed by knocking out GPR35 in cancer cells. Taken together, these findings provide compelling evidence that hyperactive genetic mutations within GPR35 contribute to a range of GI disease processes, and that inhibiting GPR35 activity may have therapeutic utility in these diseases. About ThirtyFiveBio ThirtyFiveBio Limited is a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease. The company has built scientific thought leadership in the biology of GPR35 and the role that it plays in GI disease, including digestive tract colitis and cancers. ThirtyFiveBio has leveraged its fully enabled drug discovery platform to identify multiple unique families of first-in-class small-molecule GPR35 inhibitors that it is advancing through lead optimization activities. Created by M:M Bio and Canaan Partners, the company has raised $20 million in seed financing to date. ThirtyFiveBio is headquartered at the Innovation Centre on Milton Park, a key science precinct south of Oxford, UK. For more information, please visit: About Innovate UK Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation. For more information visit Contacts: ThirtyFiveBio James Westcott Chief Executive Officer P: +44 (0)1235 644980 [email protected] Vida Strategic Partners (on behalf of ThirtyFiveBio) Tim Brons (Media) 415-675-7402 [email protected] SOURCE ThirtyFiveBio